Cann Group Akcija

Cann Group EBITDA

Vrijednost EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Cann Group (CAN.AX) na dan 17. авг 2026. je -5,07 М AUD. Prethodne godine, EBITDA (Заработак пре камата, пореза, амортизације и отписивања) je bio -14,31 М AUD — promjena od -64,61% (viši).

EBITDA

-5,07 МAUD

YoY

-64,61%

Zadnja ažuriranja:

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Cann Group je 2026 -5,07 М AUD. EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Cann Group je bio 2025 -14,31 М AUD. Pad je time -64,61% viši u odnosu na prethodnu godinu.
Access this data via the Eulerpool API

Cann Group Анализа акција

Šta radi Cann Group? Cann Group Ltd is an Australian company specializing in the production and marketing of medical cannabis. The company was founded in 2013 and is headquartered in Melbourne. The company's history began with the founding of an independent consulting firm called AusCann Group Holdings Ltd in 2014. This firm was created to inform Australian and international investors about the opportunities and possibilities in the Australian cannabis market. In 2016, a cooperation agreement was signed between AusCann and Cann Group Ltd to advance the cultivation and production of medical cannabis products in Australia. Since then, Cann Group has continuously invested in the development and growth of the Australian medical cannabis market. The company has obtained a Good Manufacturing Practices (GMP) compliance license to ensure that all products meet the highest quality and safety standards. This includes collaborating with research institutions and state health authorities to investigate the efficacy and safety of medications. Cann Group's various business areas include the production of medical cannabis, research, product development, and marketing. The company operates a cannabis cultivation facility in Cochranes Hill, Victoria, covering an area of 20 hectares. The cultivation of cannabis is carried out under controlled conditions to ensure that all products are of the highest quality and purity. The cultivated cannabis is then used to manufacture medical products such as oils, tinctures, capsules, and sprays. Cann Group also collaborates closely with research institutions and academic institutions to study the safety and efficacy of medical cannabis. The company has partnerships with the University of Melbourne, Queensland University of Technology, and Swinburne University of Technology for research on the mechanisms of cannabis, application research, and studies on the clinical efficacy of cannabis. The business model of Cann Group is based on the sale of medical cannabis products to pharmacies and medical facilities in Australia and worldwide. The company, through its license, is one of the few companies capable of producing and exporting medical cannabis for the Australian market. In addition to exporting cannabis products to Germany, New Zealand, the UK, and other countries, the sale of cannabis products to the Australian market is the largest market for Cann Group. The company offers a variety of medical cannabis products specifically developed for various medical conditions. These include products for anxiety, nausea and vomiting, pain, seizures, and many other diseases. There are also products for palliative care, which help alleviate pain and suffering in the final stages. Overall, Cann Group Ltd has played a pioneering role in the development of the Australian medical cannabis market in recent years. The company specializes in the production of medical cannabis products that meet the highest quality standards and strict regulatory requirements. The company is committed to improving the therapeutic approach to diseases and enhancing the quality of life for patients. Cann Group je jedna od najpopularnijih kompanija na Eulerpool.

Često postavljena pitanja o akciji Cann Group

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) kompanije Cann Group iznosi -5,07 М AUD u 2026. godini.

EBITDA (Заработак пре камата, пореза, амортизације и отписивања) od Cann Group se promijenio sa -14,31 М AUD na -5,07 М AUD, što predstavlja promjenu od -64,61%. Vrijednost je viši nego prethodne godine.

Na Eulerpool-u možete pronaći potpuni historijski razvoj EBITDA (Заработак пре камата, пореза, амортизације и отписивања) Cann Group od 2006. — sa godišnjim vrijednostima, grafikonima i detaljnom analizom.

EBITDA мери оперативну перформансу пре утицаја финансијске структуре, окружења пореза и не-готовинских отписивања.

EBITDA = EBIT + Амортизација и отписивање

EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s AUD je ključan faktor za investitore. Promene u ovoj metrici mogu signalizirati poboljšane ili pogoršane fundamentalne faktore, direktno utiču na cenu akcije. Na Eulopoolu, možete pratiti EBITDA (Заработак пре камата, пореза, амортизације и отписивања)'s Cann Group istorijski i u realnom vremenu.

Access this data via the Eulerpool API

Извештај о добити и губитку — Cann Group

Sve ključne metrike — Cann Group

Раст